Generic intravenous (IV) drugs are considered bioequivalent to their branded counterparts due to their 100% bioavailability upon administration. However, variations in stability among different drug products can significantly influence their therapeutic performance, even if they are pharmaceutically equivalent.
Cefuroxime, a prophylactic antimicrobial, is often used as a single-dose IV injection for patients undergoing coronary artery bypass grafting surgery. A 3 g dose typically provides sufficient serum levels to prevent infections during surgery, occasionally supplemented by a 0.75 g dose administered 12 hours post-surgery. However, when a generic version of cefuroxime was used as a cost-saving measure, there was a notable increase in the frequency of post-surgical infections, with some patients requiring admission to the intensive care unit. The reintroduction of the branded drug led to a decrease in severe postoperative infections, which again increased when the generic drug was re-administered.
Investigations found that despite chemical equivalence, the generic product underwent rapid hydrolysis, reducing its effectiveness by the time of administration. Although the exact reasons for this reduced stability were not specified, it's likely attributable to differences in formulation or the manufacturing process. This case emphasizes the importance of considering stability when evaluating the therapeutic equivalence of generic and branded drugs.
Stability-related issues often contribute to pharmaceutical nonequivalence, especially in intravenous or IV products.
Generic IV products are 100% bioavailable upon administration. So, they are considered bioequivalent if they meet pharmaceutical equivalence criteria.
However, stability varies between drug products, potentially affecting therapeutic performance.
For instance, 3 g of branded cefuroxime via a single-dose IV injection before anesthetic induction achieved sufficient serum levels to prevent surgical infections. An additional 0.75 g was administered twelve hours post-surgery.
However, using generic cefuroxime led to increased incidences of postsurgical infections, with some patients even requiring intensive care.
Investigations revealed that despite having a chemically identical composition, the generic product exhibited reduced efficacy by the time of administration due to rapid hydrolysis.
This stability issue may stem from differences in the formulation or manufacturing processes.
繁體中文
